


APPENDIX

Figure S1. PRISMA flow diagram for the selection of full economic evaluations of genetic and pharmacogenetic testing programs and systematic reviews of full economic evaluations.

Figura S1. Diagramma di flusso PRISMA relativo alla selezione delle valutazioni economiche complete dei test genetici e farmacogenetici e delle revisioni sistematiche delle valutazioni economiche complete.



References of 128 full economic evaluations

Predictive genetic testing

Hereditary breast and ovarian cancer

- Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. *J Clin Oncol* 1999; 17(2): 494-500.
- Rubinstein WS, Jiang H, Dellefave L, Rademaker AW. Cost-effectiveness of population-based BRCA 1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue. *Genet Med* 2009; 11(9): 629-39.
- Manchanda R, Legood R, Burnell M et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing. *J Natl Cancer Inst* 2014; 107(1): 380.
- Holland ML, Huston A, Noyes K. Cost-effectiveness of testing for breast cancer susceptibility genes. *Value Health* 2009; 12(2): 207-16.
- Balmaña JI, Sanz J, Bonfill X et al. Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. *Int J Cancer* 2004; 112(4): 647-52.
- Tengs TO, Berry DA. The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. *Dis Manage Clin Outcomes* 2000; 1:15-24.
- Kwon JS, Gutierrez-Barrera AM, Young D et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. *J Clin Oncol* 2009; 28(27): 4214-20.
- Heimdal K, Maehle L, Møller P. Costs and benefits of diagnosing familial breast cancer. *Dis Markers* 1999; 15(1-3): 167-73.
- Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. *J Clin Oncol* 2010; 28(4): 675-82.

Inherited colon-rectal cancer, Lynch syndrome and familial adenomatous polyposis (FAP)

- Breheny N, Geelhoed E, Goldblatt J, Ee H, O'Leary P. Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma. *Community Genet* 2006; 9(2): 98-106.
- Brown ML, Kessler LG. The use of gene tests to detect hereditary predisposition to cancer: economic considerations. *J Natl Cancer Inst* 1995; 87(15): 1131-6.
- Brown ML, Kessler LG. Use of gene tests to detect hereditary predisposition to cancer: what do we know about cost effectiveness? *Int J Cancer* 1996; 69(1): 55-7.
- Dinh TA, Rosner BI, Atwood JC et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. *Cancer Prev Res (Phila)* 2011; 4(1): 9-22.
- Kievit W, de Bruin JH, Adang EM et al. Cost effectiveness of a new strategy to identify HNPCC patients. *Gut* 2005; 54(1): 97-102.
- Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. *J Clin Oncol* 2011; 29(16): 2247-52.
- Ladabaum U, Wang G, Terdiman J et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. *Ann Intern Med* 2011; 155(2): 69-79.
- Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. *Ann Intern Med* 2010; 153(6): 368-77.
- Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. *Genet Med*, 2010; 12(2): 93-104.
- Nielsen M, Hes FJ, Vasen HF, van den Hout WB. Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations. *BMC Med Genet* 2007; 8: 42.
- Olsen KR, Bojesen SE, Gerdes AM, Lindorff-Larsen K, Bernstein IT. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. *Int J Technol Assess Health Care* 2007; 23(1): 89-95.
- Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. *Ann Intern Med* 2001; 135(8): 577-88.
- Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. *Genet Med* 2003; 5(5): 353-63.

- Resnick K, Straughn JM Jr, Backes F, Hampel H, Matthews KS, Cohn DE. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. *Obstet Gynecol* 2009; 114(3): 530-6.
- Reyes CM, Allen BA, Terdiman JP, Wilson LS. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. *Cancer* 2002; 95(9): 1848-56.
- Vasen HF, van Ballegooijen M, Buskens E et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. *Cancer* 1998; 82(9): 1632-7.
- Wu GH, Wang YM, Yen AM, Wong JM, Lai HC, Warwick J, Chen TH. Costeffectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate incidence countries. *BMC Cancer* 2006; 6: 136.

Hereditary hemochromatosis

- Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. *Am J Gastroenterol* 1999; 94(6): 1593-600.
- Cooper K, Bryant J, Picot J, Clegg A, Roderick PR, Rosenberg WM, Patch C. A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations. *QJM* 2008; 101(8): 631-41.
- El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. *Ann Intern Med* 2000; 132(4): 261-9.
- Gagné G, Reinharz D, Laflamme N, Adams PC, Rousseau F. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on costeffectiveness of testing algorithms. *Clin Genet* 2007; 71(1): 46-58.
- Rogowski WH. The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study. *Med Decis Making* 2009; 29(2): 224-38.
- Schöffski O, Schmidtke J, Stuhmann M. Cost-Effectiveness of population-based genetic hemochromatosis screening. *Community Genet* 2000 3: 2–11.

Cystic fibrosis

- Asch DA, Hershey JC, Dekay ML et al. Carrier screening for cystic fibrosis: costs and clinical outcomes. *Med Decis Making* 1998; 18(2): 202-12.
- Davis LB, Champion SJ, Fair SO, Baker VL, Garber AM. A cost-benefit analysis of preimplantation genetic diagnosis for carrier couples of cystic fibrosis. *Fertil Steril* 2010; 93(6): 1793-804.
- Lieu TA, Watson SE, Washington AE. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. *Obstet Gynecol* 1994; 84(6): 903-12.
- Rowley PT, Loader S, Kaplan RM. Prenatal screening for cystic fibrosis carriers: an economic evaluation. *Am J Hum Genet* 1998; 63(4): 1160-74.
- van den Akker-van Marle ME, Dankert HM, Verkerk PH, Dankert-Roelse JE. Costeffectiveness of 4 neonatal screening strategies for cystic fibrosis. *Pediatrics* 2006; 118(3): 896-905.
- Warren E, Anderson R, Proos AL, Burnett LB, Barlow-Stewart K, Hall J. Costeffectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program. *Genet Med* 2005; 7(7): 484-94.

Familial hypercholesterolaemia

- Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L, Bonsel GJ, Klazinga NS. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. *Eur Heart J*, 2002;23(24):1922-30.
- Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. *Health Technol Assess*, 2000;4(29):1-123.
- Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic costeffectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. *Heart*, 2011;97(14):1175-81.

Thrombophilia

- Auerbach AD, Sanders GD, Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. *Am J Med* 2004; 116(12): 816-28.
- Eckman MH, Singh SK, Erban JK, Kao G. Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: A cost-effectiveness analysis. *Med Decis Making* 2002; 22(2): 108-24.
- Marchetti M, Quaglini S, Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. *QJM* 2001; 94(7): 365-72.
- Smith KJ, Monsef BS, Ragni MV. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. *Thromb Haemost* 2008; 100(3): 447-52.

- Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. *Health Technol Assess* 2006; 10(11): 1-110.

Chromosomal abnormalities

- Armengol L, Nevado J, Serra-Juhé C et al. Clinical utility of chromosomal microarray analysis in invasive prenatal diagnosis. *Hum Genet* 2012; 131(3): 513-23.
- Harris RA, Washington AE, Nease RF Jr, Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. *Lancet* 2004; 363(9405): 276-82.
- Heckerling PS, Verp MS. A cost-effectiveness analysis of amniocentesis and chorionic villus sampling for prenatal genetic testing. *Med Care* 1994; 32(8): 863-80.
- Mersereau JE, Plunkett BA, Cedars MI. Preimplantation genetic screening in older women: a cost-effectiveness analysis. *Fertil Steril* 2008; 90(3): 592-8.
- Regier DA, Friedman JM, Marra CA. Value for money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability. *Am J Hum Genet* 2010; 86(5): 765-72.
- Trakadis Y, Shevell M. Microarray as a first genetic test in global developmental delay: a cost-effectiveness analysis. *Dev Med Child Neurol* 2011; 53(11): 994-9.

Fragile X syndrome

- Musci TJ, Caughey AB. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. *Am J Obstet Gynecol* 2005; 192(6): 1905-15.
- Toledano-Alhadeff H, Basel-Vanagaite L, Magal N et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. *Am J Hum Genet* 2001; 69(2): 351-60.

Long QT syndrome

- Perez MV, Kumarasamy NA, Owens DK, Wang PJ, Hlatky MA. Cost-effectiveness of genetic testing in family members of patients with long-QT syndrome. *Circ Cardiovasc Qual Outcomes* 2011; 4(1): 76-84.
- Phillips KA, Ackerman MJ, Sakowski J, Berul CI. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. *Heart Rhythm* 2005; 2(12): 1294-300.

Hypertrophic cardiomyopathy

- Ingles J, McGaughan J, Scuffham PA, Atherton J, Semsarian C. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. *Heart* 2012; 98(8): 625-30.
- Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, Taylor J, Watkins H. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. *Eur Heart J* 2010; 31(8): 926-35.

Others

- Little SE, Janakiraman V, Kaimal A, Musci T, Ecker J, Caughey AB. The costeffectiveness of prenatal screening for spinal muscular atrophy. *Am J Obstet Gynecol* 2010; 202(3): 253.e1-7.
- Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK. Costeffectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. *Gynecol Oncol* 2010; 119(2): 237-42.
- King CH, Fischler DF, Gerkin RD. Will genetic testing alter the management of disease caused by infectious agents? A cost-effectiveness analysis of gene-testing strategies for prevention of rheumatic fever. *Clin Infect Dis* 2002; 34(11): 1491-9.
- Higashi MK, Veenstra DL, del Aguila M, Hujuel P. The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. *J Periodontol* 2002; 73(12): 1474-84.
- Gutiérrez de Mesa E, Hidalgo I, Christidis P, Ciscar JC, Vegas E, Ibarreta D. Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children. *Mol Diagn Ther* 2007; 11(5): 313-23.
- Gordon LG, Hirst NG, Young RP, Brown PM. Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness? *Cost Eff Resour Alloc* 2010; 8: 18.
- Rubenstein JH, Vakil N, Inadomi JM. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. *Aliment Pharmacol Ther* 2005; 22(2): 135-46.
- Calvert NW, Morgan AB, Catto JW, Hamdy FC, Akehurst RL, Mouncey P, Paisley S. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. *Br J Cancer* 2003; 88(1): 31-5.

Pharmacogenetic testing

Breast cancer

- Blank PR1, Schwenkglens M, Moch H, Szucs TD. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. *Breast Cancer Res Treat* 2010; 124(2): 497-507.
- Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. *Cancer Invest* 2009; 27(10): 953-9.

- Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. *J Clin Oncol* 2004; 22(5): 854-63.
- Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. *Am J Manag Care* 2005; 11(5): 313-24. Erratum in: *Am J Manag Care* 2005; 11(8): 476.
- Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israelimanaged health-care organization. *Value Health* 2010; 13(4): 381-7.
- Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21- gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogenreceptor-positive, early-stage breast cancer in Japan. *Breast Cancer Res Treat* 2008; 112(1): 175-87.
- Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21- gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). *Breast Cancer Res Treat*, 2011;127(3):739-49.
- Lidgren M, Jönsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. *Ann Oncol* 2008; 19(3): 487-95.
- Lidgren M, Wilking N, Jönsson B, Rehnberg C. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. *Acta Oncol* 2008; 47(6): 1018- 28.
- Morelle M, Haslé E, Treilleux I, Michot JP, Bachelot T, Penault-Llorca F, Carrère MO. Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. *Int J Technol Assess Health Care* 2006; 22(3): 396-401.
- Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? *Genet Med* 2005; 7(6): 380-9.
- Retèl VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH. Costeffectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. *Eur J Cancer* 2010; 46(8): 1382-91.
- Retel VP, Joore MA, van Harten WH. Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. *Breast Cancer Res Treat* 2012; 131(2): 627-36.
- Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. *Oncologist* 2010; 15(5): 457-65.
- Woods B, Veenstra D, Hawkins N. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment. *Value Health* 2011; 14(8): 989-1001.

Colon-rectal cancer

- Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. *Clin Cancer Res* 2011; 17(19): 6338-46.
- Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. *Cancer* 2009; 115(17): 3858-67.
- Obradovic M, Mrhar A, Kos M. Cost-effectiveness of UGT1A1 genotyping in secondline, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. *Pharmacogenomics* 2008; 9(5): 539-49.
- Pichereau S, Le Louarn A, Lecomte T, Blasco H, Le Guellec C, Bourgoin H. Costeffectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. *J Pharm Pharm Sci* 2010; 13(4): 615-25.
- Shiroya T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. *Mol Diagn Ther* 2010; 14(6): 375-84.

Thromboembolism

- Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. *Ann Intern Med* 2009; 150(2): 73-83.
- Leey JA, McCabe S, Koch JA, Miles TP. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. *Am J Geriatr Pharmacother* 2009; 7(4): 197-203.
- Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis. *Thromb Haemost* 2000; 84(5): 752-7. Erratum in: *Thromb Haemost* 2000; 84(6): 1112.

- McWilliam A, Lutter R, Nardinelli C . Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. *Per Med* 2008; 5: 279–84.
- Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. *Pharmacoeconomics*, 2010;28(1):61-74.
- Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes* 2009; 2(5): 429-36.
- Schalekamp T, Boink GJ, Visser LE, Stricker BH, de Boer A, Klungel OH. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? *Clin Pharmacol Ther* 2006; 79(6): 511-20.
- You JH, Chan FW, Wong RS, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. *Thromb Haemost* 2004; 92(3): 590-7.
- You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. *Clin Pharmacol Ther* 2009; 86(5): 540-7.

Rheumatic diseases

- Kim SK, Jun JB, El-Sohemy A, Bae SC. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. *J Rheumatol* 2006; 33(7): 1266-74.
- Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. *J Rheumatol* 2002; 29(12): 2507-12.

AIDS

- Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Costeffectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. *Pharmacogenetics* 2004; 14(6): 335-42.
- Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. *Pharmacoeconomics* 2010; 28(11): 1025-39.
- Nieves Calatrava D, Calle-Martín Ode L, Iribarren-Loyarte JA, Rivero-Román A, García-Bujalance L, Pérez-Escolano I, Brosa-Riestra M. Cost-effectiveness analysis of HLAB*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. *Enferm Infecc Microbiol Clin* 2010; 28(9): 590-5.
- Sax PE, Islam R, Walensky RP at al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. *Clin Infect Dis* 2005; 41(9): 1316-23.
- Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The costeffectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. *AIDS* 2008; 22(15): 2025-33.
- Sendi P, Günthard HF, Simcock M, Ledergerber B, Schüpbach J, Battegay M; Swiss HIV Cohort Study. Cost-effectiveness of genotypic antiretroviral resistance testing in HIVinfected patients with treatment failure. *PLoS One* 2007; 2(1): e173.
- Weinstein MC, Goldie SJ, Losina E et al. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. *Ann Intern Med* 2001; 134(6): 440-50.
- Yazdanpanah Y, Vray M, Meynard J et al. The longterm benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. *HIV Med* 2007; 8(7): 439-50.

HCV

- Siebert U, Sroczynski G, Aidelsburger P et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. *Pharmacoeconomics* 2009; 27(4): 341-54.
- Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. *JAMA* 1998; 280(24): 2088-93.
- Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. *Hepatology* 1999; 30(5): 1318-24.

Inflammatory bowel disease (IBD) and gastritis

- Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A costeffectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. *Am J Gastroenterol* 2005; 100(10): 2239-47.
- Furuta T, Shirai N, Kodaira M et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of *H. pylori*. *Clin Pharmacol Ther* 2007; 81(4): 521-8.

- Lehmann DF, Medicis JJ, Franklin PD. Polymorphisms and the pocketbook: the costeffectiveness of cytochrome P450 2C19 genotyping in the eradication of *Helicobacter pylori* infection associated with duodenal ulcer. *J Clin Pharmacol* 2003; 43(12): 1316-23.
- Priest VL, Begg EJ, Gardiner SJ et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. *Pharmacoeconomics* 2006; 24(8): 767-81.

Chronic kidney disease

- Costa-Scharplatz M, van Asselt AD, Bachmann LM, Kessels AG, Severens JL. Costeffectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. *Pharmacogenet Genomics* 2007; 17(5): 359-68.
- Vegter S, Perna A, Hiddema W, Ruggenenti P, Remuzzi G, Navis G, Postma MJ. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. *Pharmacogenet Genomics* 2009; 19(9): 695-703.

Acute lymphoblastic leukemia

- Donnan JR, Ungar WJ, Mathews M, Hancock-Howard RL, Rahman P. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2011; 57(2): 231-9.
- van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez de Mesa E, Ibarreta D. Cost-effectiveness of pharmacogenomics in clinical practice: 104 a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. *Pharmacogenomics* 2006; 7(5): 783-92.

Lung cancer

- Borget I, Cadranet J, Pignon JP et al. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. *Eur Respir J* 2012; 39(1): 172-9.
- Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. *Value Health* 2009; 12(1): 20-7.
- de Lima Lopes G Jr, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Costeffectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. *Cancer* 2012; 118(4): 1032-9.

Major depressive disorder

- Olgiati P, Bajo E, Bigelli M, De Ronchi D, Serretti A. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. *Prog Neuropsychopharmacol Biol Psychiatry* 2012; 36(1): 147-54.
- Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. *Neuropsychopharmacology* 2009; 34(10): 2227-36.
- Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. *World J Biol Psychiatry* 2011; 12(7): 501-15.

Others

- Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burk W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. *Genet Med* 2007; 9(10): 695–704.
- Greeley SA, John PM, Winn AN et al. The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. *Diabetes Care* 2011; 34(3): 622-7.
- Maitland-van der Zee AH, Klungel OH, Stricker BH et al. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. *Pharmacogenetics* 2004; 14(1): 53-60.
- Reed SD, Scales CD Jr, Stewart SB, Sun J, Moul JW, Schulman KA, Xu J. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. *J Urol* 2011; 185(3): 841-7.
- Hagaman JT, Kinder BW, Eckman MH. Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. *Lung*, 2010;188(2):125-32. Erratum in: *Lung* 2011; 189(3): 259.
- Heitjan DF, Asch DA, Ray R, Rukstalis M, Patterson F, Lerman C. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. *Pharmacogenomics J* 2008; 8(6): 391-9.